Online inquiry

IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9926MR)

This product GTTS-WQ9926MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EPHA3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005233.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2042
UniProt ID P29320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9926MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11355MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ11682MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ9543MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ9323MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ8395MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ10873MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ3766MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ14817MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW